These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 37805968

  • 1. Clinical utility of a cytomegalovirus-specific T cell assay in assessing the risk of post-prophylaxis cytomegalovirus infection and post-treatment relapse.
    Dioverti MV, Bhaimia E, Yetmar ZA, Melendez DP, Misner L, Beito E, Deziel PJ, Theel ES, Razonable RR.
    Clin Transplant; 2023 Dec; 37(12):e15143. PubMed ID: 37805968
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M.
    BMC Infect Dis; 2018 Apr 16; 18(1):179. PubMed ID: 29661141
    [Abstract] [Full Text] [Related]

  • 3. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
    Jorgenson MR, Kleiboeker H, Garg N, Parajuli S, Mandelbrot DA, Odorico JS, Saddler CM, Smith JA.
    Transpl Infect Dis; 2022 Feb 16; 24(1):e13766. PubMed ID: 34799964
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation.
    Kumar D, Mian M, Singer L, Humar A.
    Am J Transplant; 2017 Sep 16; 17(9):2468-2473. PubMed ID: 28500691
    [Abstract] [Full Text] [Related]

  • 6. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
    Chiereghin A, Potena L, Borgese L, Gibertoni D, Squarzoni D, Turello G, Petrisli E, Piccirilli G, Gabrielli L, Grigioni F, Lazzarotto T.
    J Clin Microbiol; 2018 Apr 16; 56(4):. PubMed ID: 29305542
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients.
    Gardiner BJ, Chow JK, Price LL, Nierenberg NE, Kent DM, Snydman DR.
    Clin Infect Dis; 2017 Nov 29; 65(12):2000-2007. PubMed ID: 29020220
    [Abstract] [Full Text] [Related]

  • 9. Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial.
    Jarque M, Crespo E, Melilli E, Gutiérrez A, Moreso F, Guirado L, Revuelta I, Montero N, Torras J, Riera L, Meneghini M, Taco O, Manonelles A, Paul J, Seron D, Facundo C, Cruzado JM, Gil Vernet S, Grinyó JM, Bestard O.
    Clin Infect Dis; 2020 Dec 03; 71(9):2375-2385. PubMed ID: 32076718
    [Abstract] [Full Text] [Related]

  • 10. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
    San-Juan R, Navarro D, García-Reyne A, Montejo M, Muñoz P, Carratala J, Len O, Fortun J, Muñoz-Cobo B, Gimenez E, Eworo A, Sabe N, Meije Y, Martín-Davila P, Andres A, Delgado J, Jimenez C, Amat P, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Aguado JM, REIPI Network.
    Transpl Infect Dis; 2015 Oct 03; 17(5):637-46. PubMed ID: 26134282
    [Abstract] [Full Text] [Related]

  • 11. Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients.
    La Rosa C, Limaye AP, Krishnan A, Blumstein G, Longmate J, Diamond DJ.
    Transpl Int; 2011 Sep 03; 24(9):920-31. PubMed ID: 21672050
    [Abstract] [Full Text] [Related]

  • 12. Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-γ release assay in kidney transplant recipients treated with antithymocyte globulin.
    Fernández-Ruiz M, Rodríguez-Goncer I, Parra P, Ruiz-Merlo T, Corbella L, López-Medrano F, Polanco N, González E, San Juan R, Folgueira MD, Andrés A, Aguado JM.
    Am J Transplant; 2020 Aug 03; 20(8):2070-2080. PubMed ID: 31991045
    [Abstract] [Full Text] [Related]

  • 13. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients.
    Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR.
    Am J Transplant; 2010 Jan 03; 10(1):157-61. PubMed ID: 19889123
    [Abstract] [Full Text] [Related]

  • 14. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
    Korneffel K, Mitro G, Buschor K, Rees M, Ortiz J.
    Transpl Immunol; 2019 Oct 03; 56():101226. PubMed ID: 31344441
    [Abstract] [Full Text] [Related]

  • 15. Role of cytomegalovirus specific cell-mediated immunity in the monitoring of cytomegalovirus infection among living donor liver transplantation adult recipients: A single-center experience.
    Bhugra A, Khodare A, Agarwal R, Pamecha V, Gupta E.
    Transpl Infect Dis; 2023 Feb 03; 25(1):e14011. PubMed ID: 36602403
    [Abstract] [Full Text] [Related]

  • 16. Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R-): A Case Series.
    Andreani M, Albano L, Benzaken S, Cassuto E, Jeribi A, Caramella A, Giordanengo V, Bernard G, Esnault V, Seitz-Polski B.
    Transplant Proc; 2020 Feb 03; 52(1):204-211. PubMed ID: 31889538
    [Abstract] [Full Text] [Related]

  • 17. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.
    Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, Venkataraman S, Humar A.
    Am J Transplant; 2009 May 03; 9(5):1214-22. PubMed ID: 19422346
    [Abstract] [Full Text] [Related]

  • 18. Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated With Antithymocyte Globulin: A Randomized Clinical Trial.
    Páez-Vega A, Gutiérrez-Gutiérrez B, Agüera ML, Facundo C, Redondo-Pachón D, Suñer M, López-Oliva MO, Yuste JR, Montejo M, Galeano-Álvarez C, Ruiz-San Millan JC, Los-Arcos I, Hernández D, Fernández-Ruiz M, Muñoz P, Valle-Arroyo J, Cano A, Rodríguez-Benot A, Crespo M, Rodelo-Haad C, Lobo-Acosta MA, Garrido-Gracia JC, Vidal E, Guirado L, Cantisán S, Torre-Cisneros J, TIMOVAL Study Group.
    Clin Infect Dis; 2022 Mar 09; 74(5):757-765. PubMed ID: 34228099
    [Abstract] [Full Text] [Related]

  • 19. Reliability of QuantiFERON®-CMV in predicting CMV recurrence in heart transplant recipients: A single-center retrospective study.
    Sermet K, Goeminne C, Hantz S, Assaf A, Faure E, Lazrek M, Faure K, Alain S, Vuotto F.
    Clin Transplant; 2023 Dec 09; 37(12):e15109. PubMed ID: 37641575
    [Abstract] [Full Text] [Related]

  • 20. A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation.
    Westall GP, Cristiano Y, Levvey BJ, Whitford H, Paraskeva MA, Paul E, Peleg AY, Snell GI.
    Transplantation; 2019 May 09; 103(5):1005-1013. PubMed ID: 30247316
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.